EYPT at a glance
EyePoint, Inc. (EYPT, SEC CIK 1314102) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), EyePoint, Inc. (EYPT) reported revenue of $31.4 million (down 27.5% from FY2024) and a net loss of $232.0 million. Diluted EPS was -$3.17.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding EyePoint, Inc. (EYPT) shares worth $388.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Zaderej Karen L. on August 18, 2026 of 10,600 shares at $4.93 per share.
- In the last 90 days, EYPT insiders reported 1 open-market purchase ($52K) and 0 open-market sales ($0) on Form 4, a net purchase of $52K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $31.4M
- −27.5% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$52K
- 13F holders
- 27 funds
- $388.2M · −2 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
- New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
- Strategic shift: Transition from early to pivotal late-stage global Phase 3 trials with enrollment completion in two wet AMD studies (LUGANO, LUCIA) and initiation of two DME studies (COMO, CAPRI)
- Quantitative metric: Over 900 patients enrolled across two Phase 3 wet AMD trials, additional ~480 patients planned for Phase 3 DME trials; Phase 2 VERONA trial showed +10.3 letters BCVA improvement in subgroup vs +3.0 aflibercept
- Noteworthy fact: DURAVYU's intracellular multi-MOA acting on VEGF receptors plus anti-inflammatory IL-6 signaling constitutes a new treatment paradigm with potential 6-month sustained delivery reducing treatment burden by over 85%
Risk Factors
- DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
- Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
- Manufacturing risk: inability to scale DURAVYU production could delay Phase 3 trials and commercialization
- Competitive risk: approval and market acceptance of DURAVYU may be impacted by alternative wet AMD treatments and generics
- Liquidity risk: $306.1M cash runway likely sufficient only through Q4 2027, requiring uncertain future capital raises that may dilute shareholders
Management Discussion & Analysis
- Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
- Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
- Best segment: Royalty income $13.0M (+708%); Worst: License/collab revenue down $21.8M to $16.7M
- Financing: Raised $172.5M via public offering + $11.6M ATM sales; cash and securities $306.1M at year-end; Operating cash outflow $240.1M; no buybacks or dividends disclosed
- Outlook: Phase 3 DURAVYU trials enrollment complete, data expected mid-2026; first DME patient dosed Feb 2026; settled DOJ investigation in principle with ~$4.7M payment; cash runway into Q4 2027
AI summary of the EYPT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0.5M, down 90% YoY from $5.3M
- Net loss $94.5M vs $59.4M YoY; operating loss $97.4M vs $62.2M
- DURAVYU R&D spending $58.0M vs $37.3M, the largest program investment
- Cash, equivalents, and marketable securities $180.5M; funding expected into Q4 2027
- Operating cash outflow $142.9M vs $115.7M; ATM proceeds $19.6M net in six months
Risk Factors
- New litigation risk triggered by March 20, 2026 complaint against Ocular over alleged false or misleading DURAVYU statements
- Legal exposure increased after Ocular’s April 13, 2026 answer sought dismissal with prejudice and attorneys’ fees
- Regulatory-compliance risk reflected in July 2026 settlement and Corporate Integrity Agreement with HHS OIG and TRICARE
- Near-term market risk from volatile trading and low volume, potentially limiting desired liquidation timing and price
- Financial dilution risk from additional shares issued upon outstanding options, warrants, or stock-unit settlement
AI summary of the EYPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Updated investor presentation posted September 10, 2026
- Exhibit 99.1 contains the presentation and may include updated business, pipeline, or financial information
Item EX-99.1: Item EX-99.1
- LUGANO missed full-population non-inferiority, a major regulatory setback despite strong anatomic control and durability
- Nine DURAVYU-arm eyes lost ≥15 letters from non-wet-AMD causes, driving the endpoint; excluding them achieved non-inferiority with nominal p=0.0096
Item 8.01: Other Events
- Topline LUGANO Phase 3 data announced for DURAVYU in wet AMD
- Results represent a pivotal clinical milestone with potential regulatory and commercial implications
Item EX-99.1: Item EX-99.1
- LUGANO’s full-dataset primary endpoint failed, creating regulatory and investor risk despite favorable secondary outcomes
- Ad hoc analysis excluding 9 of 211 patients with unrelated vision loss showed non-inferiority versus aflibercept, nominal p=0.0096
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Updated investor presentation provides additional business and corporate information
Item EX-99.1: Item EX-99.1
- Q2 revenue $0.5M vs $5.3M, reflecting reduced license-related revenue and limited commercial sales
- Operating expenses rose to $97.9M from $67.6M, driven by DURAVYU Phase 3 trials and manufacturing scale-up
AI summaries of EYPT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EYPT
Don't miss the next EYPT filing
- Alerts as it files. A push when EYPT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EYPT, by share count.
- Ask anything. An AI agent that reads every EYPT filing and answers with sources.
EYPT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Elston George | G | Aug 20, 2026 | 64,953 | - |
| Elston George | J | Aug 20, 2026 | 5,000 | - |
| Elston George | J | Aug 20, 2026 | 5,000 | - |
| Elston George | G | Aug 20, 2026 | 64,953 | - |
| Zaderej Karen L. | Buy | Aug 18, 2026 | 10,600 | $4.93 |
| Duker Jay S. | M | Jul 10, 2026 | 16,667 | - |
| Duker Jay S. | F | Jul 10, 2026 | 8,059 | $14.72 |
| Duker Jay S. | M | Jul 10, 2026 | 16,667 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $43.3M | $31.4M |
| Operating Income | - | -$145.9M | -$243.4M |
| Net Income | -$70.8M | -$130.9M | -$232.0M |
| Op. Margin | - | -337.1% | -776.0% |
| Net Margin | - | -302.4% | -739.4% |
| Balance Sheet | |||
| Total Assets | $355.2M | $418.5M | $364.0M |
| Equity | - | $336.5M | $306.1M |
| ROE | - | -38.9% | -75.8% |
| Per Share | |||
| EPS | $-1.82 | $-2.32 | $-3.17 |
| Cash Flow | |||
| Operating CF | - | -$126.2M | -$240.1M |
| CapEx | $3.5M | $4.1M | $3.3M |
Source: XBRL data in EyePoint, Inc. (EYPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate EYPT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $388.2M |
| Q1 2026 | 29 | $336.5M |
| Q4 2025 | 25 | $335.7M |
| Q3 2025 | 23 | $320.9M |
| Q2 2025 | 24 | $214.6M |
| Q1 2025 | 19 | $96.1M |
| Q4 2024 | 15 | $104.2M |
| Q3 2024 | 13 | $74.5M |
- Two Sigma Investments+750.8K (+174%)
- Dimensional Fund Advisors+440.6K (+110%)
- Ameriprise Financial+425.1K (+100%)
- BlackRock+285.9K (+4%)
- State Street Corp+260.3K (+12%)
- Morgan Stanley−759.4K (-69%)
- Bank of America Corp−318.4K (-83%)
- Franklin Resources−241.5K (-5%)
- Goldman Sachs Group−234.6K (-34%)
- FMR LLC (Fidelity)−103.3K (-80%)
- Renaissance Technologies LLC−117.3K
- AQR Capital Management−17.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 175 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EYPT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 10, 2026 | - | Analysis | - |
| SC 13G | Sep 8, 2026 | - | - | |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| SC 13G | Aug 12, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| SC 13G | Jun 3, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 20, 2026 | - | - | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Mar 24, 2026 | - | - | - |
| 8-K | Mar 20, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
EYPT SEC filings: frequently asked questions
Are EYPT insiders buying or selling?
In the last 90 days, EyePoint, Inc. (EYPT) officers, directors and 10% owners reported 1 open-market purchase worth $52,258 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EYPT stock?
As of June 30, 2026, the largest EyePoint, Inc. (EYPT) holders among the 13F filers tracked by SignalX were BlackRock ($106.7 million), Franklin Resources ($68.7 million), Vanguard Capital Management LLC ($51.9 million), State Street Corp ($33.7 million), Citadel Advisors LLC ($28.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EYPT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), EyePoint, Inc. (EYPT) reported revenue of $31.4 million (down 27.5% from FY2024) and a net loss of $232.0 million. Diluted EPS was -$3.17. The figures come from the XBRL data in the 10-K.
What are the main risks in EYPT's latest 10-K?
In the 10-K filed March 5, 2026, EyePoint, Inc. (EYPT) flagged: DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026. Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027. (AI summary of the Risk Factors section.)
What did EYPT report in its latest 8-K?
EyePoint, Inc. (EYPT) filed an 8-K on September 10, 2026 reporting Item 8.01 (Other Events). Updated investor presentation posted September 10, 2026.
What are the latest EYPT SEC filings?
EyePoint, Inc. (EYPT) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on August 24, 2026.
What is EYPT's SEC CIK number?
EyePoint, Inc. (EYPT)'s SEC Central Index Key (CIK) is 1314102. EDGAR lists every EYPT filing under that number.
Ask anything about EYPT
The research agent reads EYPT's filings, financials, insider trades and 13F holders, then answers with sources.